Introduction
Hepatitis A (HepA) is one of the most common forms of acute viral liver infection and results in approximately 1.5 million clinical cases annually worldwide [1] [2] [3] . This self-limiting disease accounted for 34,000 deaths globally in 2005 [4] but was three times higher in 2010, when 102,000 deaths occurred [5] . HepA was reported to be highly endemic in regions such as South and Central America, the Middle East, South-East Asia and Africa [6, 7] . However, a shift in the endemicity towards intermediate was observed in many regions including Asia, Latin America, Eastern Europe and Middle East [7, 8] . This shift may increase the probability of acquiring HepA infection in older susceptible individuals, which may lead to outbreaks and higher severity; therefore, the World Health Organisation (WHO) recommends widespread vaccination [6] [7] [8] [9] .
The inactivated hepatitis A vaccines (HAV); Havrix ® (GSK Vaccines, Belgium) and Vaqta ® (Merck) are licensed in Europe and the United States, Epaxal ® (Crucell) in Switzerland and Argentina and Healive is licensed in China [6, 10] . Havrix ® (1440 ELISA units per millilitre [ml] suspension) and Havrix ® junior (720 ELISA units in 0.5 ml suspension) are two variants of the same vaccine with varying viral antigen content. Havrix ® junior is a two-dose inactivated vaccine that was implemented for the first time in Latin America in 2007 and administered to children in Panama since then, through a Universal Mass Vaccination (UMV) programme [11] . The first dose is recommended between 12-18 months of age and the second dose, 6-12 months after the first dose [11] . Previous studies suggest that national immunization programmes with one or two-dose vaccination schedules resulted in reduction of HepA rates [12] [13] [14] [15] [16] [17] .
Our aim was to assess the impact of HAV when given as a twodose schedule. Further, we assessed the trend in the incidence and frequency of HepA cases over time to describe the characteristics and clinical outcomes of acute hepatitis cases during the post-vaccination period.
Methods
Assessment of vaccine impact in terms of reduction in the HepA burden of disease was conducted using two different methodologies. The first method (time-trend analysis) employed a passive surveillance system using the retrospective national hospital admission data to assess the direct and indirect impact of HepA vaccination over a 10-year period (2000-2010) , including the impact of the vaccine in different regions. The second methodology (descriptive analysis) was an active hospital-based surveillance for prospective data collection on the occurrence of confirmed cases of acute HepA cases during the post-vaccine introduction period (2009) (2010) (2011) . Both methods were used to describe the vaccine impact in various age groups (first method: all age groups; second method: <15years).
Time-trend analysis
The national Epidemiologic Surveillance System of the Ministry of Health (MoH) databases indicated that HepA and unspecified hepatitis are notifiable diseases in Panama [18] . Reported number of HepA and unspecified hepatitis cases was collected using this database. It was considered that most of the unspecified hepatitis cases would correspond to HepA cases. A systematic analysis was performed on Panamanian population data (characterised by year, age and region) during 2000-2010. Aggregated data for HepA and unspecified hepatitis with vaccine dose information were analysed for three time periods; baseline period (2000) (2001) (2002) (2003) (2004) (2005) (2006) , transition year (2007) and post-vaccine introduction period (2008) (2009) (2010) .
Serological analysis is usually done to confirm HepA cases as per local algorithm. However, unconfirmed cases were reported as unspecified hepatitis which corresponds to an acute liver inflammation, mostly caused by HepA virus infection characterized by destruction of liver cells and presence of inflammatory cells in liver tissue. These outcomes were extracted using the International Classification of Diseases (ICD) codes; ICD 10 code B15.9 and ICD 9 code 070.1 was used to denote 'hepatitis A without hepatic coma' and ICD 10 code B19.9 and ICD 9 code 070.9 was assigned to 'unspecified hepatitis without hepatic coma', as reference [19, 20] .
For incidence estimations, we collected data on population by age group, year and region from the Directorate of Statistics and Census of the National Controller Office (Contraloría General de la República) [21] . Data were grouped by region (West, Central, Panama and North-East) and age (<1 year, 1-4 years, 5-9 years, 10-14 years, 15-19 years, 20-24 years, 25-49 years and ≥50 years) and year of the study. No exclusion criteria were applied for the time-trend analysis.
Vaccine dose information was provided by the Expanded Programme on Immunization for years from 2007 to 2010 and vaccine coverage was calculated at six months interval. Partial vaccine coverage population included subjects who had received at least one vaccine dose and the complete vaccine coverage population included those who had received both vaccine doses. Denominator data for vaccine coverage per study year were derived from children who aged less than one year in the previous year.
The outcome of the time-trend analysis was the occurrence of hepatitis-related outcomes in the post-vaccine introduction period (2008-2010) as compared with the baseline period (2000) (2001) (2002) (2003) (2004) (2005) (2006) and the incidence of hepatitis-related outcomes by year, age and region. The annual incidence of hepatitis-related outcomes was calculated per 100,000 subjects with 95% confidence intervals (CI).
Year-wise comparisons were made between the mean and median for number of cases and incidences for baseline and the postvaccine introduction period.
Negative binomial regression (NBR) model was used to compare trends in the number and incidence of hepatitis-related outcomes under study to assess vaccination impact [22, 23] . To account for the actual vaccination impact, the already existing trend of reduced HepA cases was compared with the expected trends derived from the NBR model. The covariates included for this mathematical model were year, age group, region and vaccination period (baseline period = 0, transition period = 1 and post-vaccination period = 2). p Values were calculated for the regression coefficients (or rate of change) in the hepatitis-related outcomes and values less than 0.05 were considered significant. The same model was also used to predict number of cases and incidence of hepatitisrelated outcomes in a hypothetical situation, where the HAV was not included in UMV.
Hospital-based surveillance
The hospital-based active surveillance was conducted between July 2009 and October 2011 at two hospitals located in Panama City (Hospital Del Niño [HDN] and Hospital de Especialidades Pediatricas [HEP]) and one hospital (Hospital Integrado San Miguel Arcangel [HISMA]) located in the neighbourhood of San Miguelito found on the outskirts of Panama City. These hospitals had a total catchment population of over one million, derived from Panama City neighbourhoods where the majority of HepA cases were reported. This surveillance aimed to validate the reported outcomes from the passive reporting system. Children with clinical diagnosis of possible acute HepA (children between >1 month and <15 years of age who attended one of the designated hospitals for an acute disease characterized by discrete onset of symptoms [dark urine, anorexia, malaise, extreme fatigue and abdominal pain] and jaundice) were eligible for study inclusion. Potential participants with confirmed diagnosis of non-viral hepatitis were excluded.
Blood samples were collected from all enrolled subjects and serum was tested for transaminase levels. Serological diagnosis was done at the hospital laboratory where each participant was enrolled.
A The occurrence of confirmed acute HepA cases and percentage of IgM anti-HepA virus positive cases were analysed by year, age group and vaccination status for the hospital-based surveillance population.
All statistical analyses for both methodologies were performed using Statistical Analysis System (SAS) Version 9.2.
Ethical aspects
The studies were conducted in accordance with the International Conference on Harmonisation guideline for Good Clinical Practice, the Declaration of Helsinki and local rules and regulations. The studies also complied with the International Guidelines for ethical review of epidemiological studies. For the subjects included in the hospital-based surveillance, written informed consent was obtained from a parent/guardian before the study started. The protocol and other documents associated with both the methodologies were reviewed and approved by the Institutional Review Board and Independent Ethics Committee of Panama.
Results

Epidemiologic surveillance system databases and time trend analyses
Between 2000 and 2010, a total of 12,665 viral hepatitis cases (HepA = 2587; unspecified hepatitis = 10,078) were recorded. In 2000, there were 2769 cases (96.9 per 100,000 subjects) which reduced to 941 cases (28.7 per 100,000 subjects) by 2006. An additional reduction in cases was also observed during 2008 (446 cases [13.1 per 100,000 subjects]), 2009 (271 cases [7.9 per 100,000 subjects]) and 2010 (130 cases [3.7 per 100,000 subjects]) in comparison to the baseline mean incidence of 51.1 per 100,000 subjects.
Mean number (±Standard Deviation [SD]) of viral hepatitis cases during the baseline period (2000) (2001) (2002) (2003) (2004) (2005) (2006) and post-vaccination period (2008-2010) were 1565 (±588) and 282.3 (±158), respectively. Compared to the baseline mean, there was an overall mean reduction of 82% and among all 4 regions, highest reduction (85%) was observed in Panama. The occurrence of HepA cases and unspecified hepatitis cases also gradually reduced (Fig. 1) .
Reduction in the incidence of hepatitis-related outcomes was also observed among all age groups during the post-vaccination period (Fig. 2, Supplementary Table 1 ). In Panama the incidence of viral hepatitis also reduced during the post-vaccination period: 2008 (11.0 per 100,000 subjects), 2009 (11.1 per 100,000 subjects) and 2010 (3.1 per 100,000 subjects).
A 90% reduction in hepatitis A incidence in the vaccinated population was noted, and 87% in the general population.
The observed viral hepatitis-related outcome (38.1% in 2008; 56.5% in 2009; 75.8% in 2010) was lower than expected during post-vaccination period (Fig. 3 ). Using this model, an additional impact of vaccination after 2007 was also confirmed when the overall viral hepatitis incidence was observed to be 3.7 per 100,000 in 2010 instead of the expected incidence of 14.6 per 100,000 ( Fig. 4) . A significant reduction (58%; p < 0.0001) in the incidence of overall hepatitis-related outcome was also observed (after adjusting for year, age and region effect) during 2008-2010 as compared with baseline period (2000) (2001) (2002) (2003) (2004) (2005) (2006) . A decline in incidence of HepA cases by 52% (p = 0.0054) and unspecified hepatitis cases by 62% (p < 0.0001) was observed in post-vaccination period compared to baseline period (Table 1) . During 2000-2010, a significant decline (p < 0.01) in the occurrence of overall viral hepatitis-related outcome was observed in subjects aged <1 year and ≥20 years as compared to the subjects aged 1-4 years (targeted vaccine age group).
Between 2007 and 2010, 241,288 first and 129,720 second doses of HAV were administered in Panama via the Expanded Program on Immunisation. Vaccine coverage among subjects who received partial vaccination was minimum in 2010 (70.7%) and maximum (99.8%) in 2008. The vaccine coverage of 66.4% was observed in subjects who received complete vaccination in 2009 ( Fig. 1 ). 
Hospital-based surveillance
Discussion
HepA virus infection and the prevalence of anti-HepA virus antibodies are strongly influenced by the economic and sanitary condition of the region [5, 7, 24] . Improved sanitation and accessible safe drinking water decreases child morbidity and mortality rates, increases the mean age of infection [4, 5, 24] , thereby increasing the risk of getting infected later in life [24] . This has been evidenced by the endemicity shift of HepA as per recent reports in Latin American countries [9, 24, 25] . Hence, the strategy to introduce HepA vaccination into the UMV in Panama was warranted.
WHO recommends a two-dose inactivated HAV that should be given at age ≥1 year [26] . Some countries may consider a single dose schedule as it is believed to show high immune response [14] . However, two-dose HAV is still preferred for immunocompromised individuals and those at substantial risk of contracting HepA [26] as evidenced in Israel [16] . Both long-term [27, 28] and modelbased studies [29, 30] suggested a two-dose HAV induced antibody persistence for at least 15 and 40 years after primary vaccination, respectively. There are also reports of long-term persistence of 17 years with a three-dose vaccination schedule showing protective HAV antibody levels [31] . Additionally, WHO recommends that the Strategic Advisory Group of Experts (SAGE) Hepatitis A Working Group should continue monitoring the long-term protection and HAV impact either used in single or two-dose schedules [32] .
The impact of two-dose schedule of HAV was evaluated for the first time in Panama after three years of vaccine introduction which was in line with the WHO recommendation. Our results showed a decline in the number of hepatitis-related outcomes in Panama over time (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) .Though a decreasing trend was observed, supporting the major sanitary improvements in early 2000's reported by the Ministry of Health, Panama [33], a greater decline in the incidence of HepA cases after 2007 was noted. Therefore, we believe reduction during the post-vaccination period was due to the vaccine's effect. NBR model showed that the observed viral hepatitis cases were substantially lower than the expected cases, thereby demonstrating vaccination impact. [15, 16] . Although in 2010, the vaccine coverage for the first dose was 71% and only 40% for complete vaccination due to vaccine supply issues in Panama. However, our surveillance reports indicated a 91.7% reduction in hepatitis-related outcomes in all age groups (including adolescents and elderly) compared to the baseline mean suggesting a possible high degree of vaccine-induced herd protection. Following HepA immunization of toddlers in the United States, a reduced number of outbreaks was observed [36] . After the implementation of routine HepA vaccination across 17 states in the United States, despite low vaccine coverage (25% to 50%), a large decrease in the incidence of HepA cases was observed [37] [38] [39] . Israel experienced a remarkable decrease in the number of HepA cases during 2001-2005 by employing routine HepA vaccination among toddlers [12, 16] . Although a lesser proportion of Israeli children received the complete HepA vaccination course (77% vaccine coverage), marked herd protection among children up to 3 years of age was observed [12] .
Additionally, there was a smaller difference in first and second dose vaccine coverage during the first year than the second year. Thus, confirming a substantial reduction in HepA transmission rates even with low coverage, supporting the fact that HAV offers protection against infection and viral excretion, also seen in animal models [38] .
Our studies had some limitations. For the trend analysis, data used from passive surveillance system for the retrospective timetrend analysis might be an underestimation of disease burden. The underestimation could be due to lack of specificity in laboratory tests used for confirmed HepA cases. Regarding hospital-based surveillance; conducted in only three sentinel reference hospitals might not completely represent the diversity of socio-economic conditions in Panama. To overcome these limitations, future studies might be necessary including primary care facilities around the sentinel hospitals.
Strengths include the combination of retrospective time-trend analyses and active hospital-based surveillance to document the vaccination impact which made our results robust. Furthermore, active surveillance was performed at sentinel hospitals postvaccine introduction that was reconciled with passive surveillance to detect any potential under-reporting in the surveillance system. As a result, no under-reporting was noted.
Our study suggested that the introduction of a two-dose HAV has contributed to the reduction in the overall incidence of hepatitisrelated outcomes in Panama. Impact of HAV in all age groups in both the settings suggested herd protection in the early phases of the vaccine implementation. Additional monitoring is required to document a sustained long-term effect of the vaccine.
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